The ValIndex Swiss Deal Count, our weekly tally of M&A-relevant commercial-register filings, reached 303 in the week of 29 June to 3 July 2026, the highest weekly count we have recorded and roughly double the prior week's level. Swiss merger law requires a fresh interim balance sheet once the accounts behind a merger are more than six months old, which makes 30 June the effective signing deadline for deals built on 31 December books.
ValIndex research: of the 38,913 audited companies in the Swiss Commercial Register, 12,362 (32%) would have no valid signature pair the day their principal signatory dies. Two of the four watch-component makers acquired by VAM Investments this week sat in those risk tiers.
Ipsen agreed on 1 July 2026 to acquire Zurich biotech Memo Therapeutics for EUR 200 million upfront and up to EUR 700 million with milestones, one of the larger Swiss biotech exits of 2026. The City of Zurich split SAP framework awards of roughly CHF 40 million across five vendors in the week's largest procurement prints.
7Press-Reported Deals+17% WoW
603Distress Events+23% WoW
2Startup FundingCHF 8.7M
20Succession Signals+186% WoW
1139New Registrations+18% WoW
2853Board Changes+40% WoW
The Swiss watch industry restructured from both ends this week. At the top, Damiani took Baume & Mercier, a maison founded in 1830, out of the Richemont stable. At the bottom, Milan's VAM Investments created Groupe Chaumont by acquiring four component makers at once: Efteor, Le Composant, Telos Watch and Henri Robert, more than one hundred employees across the Jura arc. The buyers are Italian, the debt is Swiss, and more add-ons are the stated plan.
Why do these firms sell? Our board-paralysis study measured one structural answer: of 38,913 audited Swiss companies, 32 percent would have no valid signature the day their principal director dies. Check this week's targets against that data. Telos Watch ran as a two-man board where neither partner can sign alone. Henri Robert paired one individual signer with a deputy who cannot act without him. Two of the four companies VAM just bought sat in the exact failure modes the study counts, visible in the register years before a buyer arrived.
The same arithmetic closed smaller deals. FRISAG, a Zug specialty-chemicals maker founded in 1963, went to Max Lehner AG: its seller is a second-generation owner who is also the company's only registered director. The week's marquee exit shows the opposite pole: Ipsen is paying up to 700 million euros for Zurich's Memo Therapeutics, a syndicate-built company engineered from day one to be sold.
Underneath the named deals, the register had its loudest week since our count began: 303 M&A-relevant filings, roughly double a normal week. The reason is mechanical. Swiss merger law requires a fresh interim balance sheet once the accounts behind a merger are more than six months old, so contracts built on 31 December books had to be signed by Tuesday. The filings show the stampede: agreement after agreement dated mid to late June, balance sheet per 31 December 2025. One last pattern before you go: Italy bought Swiss three times this week, the component makers, the maison, the private-banking software. Different buyers, same read. Fragile governance and retiring founders reprice Swiss assets, and the register shows both to anyone who looks.
The balance sheets nobody publishes
Absorption filings are involuntary disclosure, and this week the register printed three balance sheets you will not find in any press release. Bruker Switzerland absorbed Chemspeed Technologies, the Fuellinsdorf lab-automation firm it bought in 2021, and the filing states the absorbed company was undercapitalised and overindebted: CHF 61.6 million of assets against CHF 99.6 million of third-party liabilities, with the auditor confirming Bruker holds free equity covering the shortfall. Bell Schweiz absorbed EISBERG Holding with a CHF 8.5 million excess of liabilities, backed by subordination declarations. And the largest transfer of the week was nearly invisible: Baloise Leben moved CHF 25.47 billion of assets onto Helvetia's life entity, the register's matter-of-fact record of the Helvetia Baloise integration. Intragroup debt often explains such structures, and none of this implies operating distress. But it is real financial disclosure of otherwise silent companies, and it only exists in the register.
Pre-Deal Signals — moves that precede transactions
Jun 30
Rubix Switzerland AGLU· Industrial Distribution
The Swiss arm of Advent-owned industrial-distribution group Rubix, formed in 2024 from the century-old distributors Pluess and Montalpina, replaced PricewaterhouseCoopers with the local Lufida Revisions AG.
The group is in corporate motion: a Neuberger Berman-led minority stake and the ERIKS UK acquisition in November 2025, a new group CEO after 17 years, and continued bolt-ons. A statutory-minimum audit at the Swiss subsidiary most plausibly tracks post-merger cost rationalisation; it is worth watching either way.
negative
Jul 2
terralayr AGZG· Energy Infrastructure
The Zug battery-storage developer doubled its share capital in a 2 July filing, with no accompanying announcement.
terralayr announced a EUR 192 million round led by Eurazeo in January. The register entry is consistent with that round closing in tranches: the filings show the money actually arriving, which the January press release could not.
bullish
Jun 30
Polaroid Therapeutics AGZH· Life Sciences
The Schlieren antimicrobial-polymer biotech, founded 2022 by Ran Frenkel and Anne Graham, raised its share capital by 76% in a 30 June filing. No financing has been announced.
An uneven capital increase of this shape is consistent with a priced equity round or a convertible conversion. The company has reported no institutional funding to date, so the register is currently the only public record that new money arrived.
bullish
Jun 29
conactive AGZG· Technology & Software
The Baar SAP consulting and data boutique, owner-managed since 1997, converted from GmbH to AG and raised capital from CHF 26,000 to CHF 100,000.
A conversion to AG at the statutory minimum after 29 years as a GmbH reads as structural maturation: succession-readiness, client optics, or preparation for a transaction. No growth event has been announced.
bullish
Jul 2
ASE (Analysis Simulation Engineering) AGZH· Technology & Software
The Zurich provider of AI people-counting and passenger-flow analytics, in the register since 1996 and claiming more than 150 clients including Deutsche Bahn, SNCF and Migros, moved to CHF 100,000 capital with a statute change.
A profitable-looking niche analytics firm restructuring its legal shell after three decades, with a new board member appointed in January. The same professionalisation pattern that often precedes outside capital or a sale.
bullish
Procurement Prints — federal awards
Jun 30
Puzzle ITC AGBE
Puzzle ITC AG wins a CHF 13.4M enterprise Kubernetes platform contract with Kanton Luzern’s IT department, cementing its role as a key cloud-native infrastructure provider to Swiss cantons.
3 federal awards in 2026 · 9 tracked total · CHF 31M lifetime
CHF 13.4M
Jul 1
System Partners GmbHZH
System Partners GmbH wins a CHF 10.0M contract with the City of Zurich’s Organisation und Informatik (OIZ) for job automation and managed file transfer, deepening its lock-in with Switzerland’s largest city.
CHF 10.0M
Jul 1
PricewaterhouseCoopers AGZH
PricewaterhouseCoopers AG, the Swiss arm of the Big Four consulting giant, secures a CHF 8.08M SAP services contract with the City of Zurich’s IT department, deepening its entrenched role as the municipality’s digital core provider.
2 federal awards in 2026 · 10 tracked total · CHF 28M lifetime
CHF 8.1M
Jul 1
ConVista Consulting AGZH
SAP specialist ConVista Consulting AG wins a CHF 8.0 million SAP services contract with the City of Zurich’s IT department, cementing its grip on the Swiss financial capital’s core municipal IT backbone.
CHF 8.0M
Jul 1
Swisscom (Schweiz) AGBE
Swisscom, Switzerland’s dominant telecoms group, wins a CHF 7.95 million SAP services contract with the City of Zurich’s IT department, reinforcing its lock on mission-critical public-sector digital infrastructure.
9 federal awards in 2026 · 43 tracked total · CHF 457M lifetime
CHF 7.9M
The Tape — 8 transactions
Press reported in the mediaReg commercial-register filing, value = net assets
Jun 30
PRESS
VAM Investments← Groupe Chaumont (Efteor, Le Composant, Télôs Watch, THA)NE
Deal of the Week. Milan private equity firm VAM Investments created Groupe Chaumont, a Neuchatel-based platform, by acquiring four Swiss high-end watch-component suppliers at once: Efteor and Le Composant of Bassecourt (precious-metal cases, clasps, oscillating weights, bracelets), Telos Watch of La Chaux-de-Fonds (movements and complications) and Henri Robert of La Chaux-de-Fonds (precision cutting tools). Founders reinvested; ex-Bulgari Watches chief Umberto Macchi di Cellere leads the group. Raiffeisen Schweiz and Luzerner Kantonalbank financed. More add-ons are planned.
French pharma group Ipsen signed a definitive agreement on 1 July to acquire Memo Therapeutics, the Schlieren-based ETH Zurich spin-off behind potravitug, a first-in-class Phase II antibody against BK polyomavirus in kidney-transplant recipients. EUR 200 million upfront, milestones to above EUR 700 million, closing expected in Q3. The Swiss venture syndicate exits (Pureos, Swisscanto, Kurma, Ysios, Vesalius among others, roughly $97 million raised); the DROPZYLLA discovery platform is carved out into a new entity retained by the selling shareholders. One of the larger Swiss biotech exits of 2026.
Up to EUR 700M (USD 796M), EUR 200M upfront (deal value)
Italian jeweller Damiani completed its 100% acquisition of Geneva watchmaker Baume & Mercier from Richemont on 1 July, signed 22 January. Richemont provides interim operational services; Damiani plans to push the brand, founded in 1830, through its Rocca retail network and selected mono-brand boutiques. A rare full exit of a maison from the Richemont stable, and the top-of-market bookend to the same week's component-layer consolidation.
Italian wealthtech Objectway acquired FNZ's Swiss private-banking technology business, the former New Access, with more than 160 professionals and software used by over 40 private banks across Switzerland, Liechtenstein, Luxembourg, Monaco and the Bahamas. Vincent Jeunet becomes CEO of the rebranded Objectway Switzerland. FNZ is reversing its 2022 New Access purchase; the third Italian acquirer in the Swiss market this week.
Zurich's Max Lehner AG, maker of the maxolen and carlack surface-care lines, took over the operating business of FRISAG AG of Neuheim, a specialty-chemicals producer founded in 1963, effective 1 July. Second-generation owner Urs Schildknecht, the company's sole registered director, framed the sale as securing continuity for a business his father founded. Recipes, staff and the FRISAG brand are retained. A textbook Swiss succession exit of exactly the sole-director shape our research keeps measuring.
Lugano's Banca Credinvest took a 19.5% stake in Carthesio, one of Ticino's main independent asset managers: 23 professionals, over CHF 1 billion under management, FINMA-authorised since 2007, closely tied to the Bianchetti family. Carthesio becomes wealth-management advisor to the bank. The register shows Carthesio tidied its structure in advance, absorbing sister company Carthesio M.C. under a May merger contract.
The register recorded completion of the acrevis and Regiobank Männedorf merger on 30 June: CHF 430.4 million of assets and CHF 389.1 million of liabilities moved to the St. Gallen bank. Terms from the February announcement: 17 acrevis shares plus CHF 200 in cash per Regiobank share, a transaction volume of CHF 25.8 million, retroactive to 1 January. Männedorf continues as an acrevis branch with staff retained. Regional-bank consolidation keeps grinding: three Emmental Raiffeisen banks and two St. Gallen-area Raiffeisen banks also merged this year.
CHF 430.4M (net assets)
Jun 29
REG
Universitäre Psychiatrische Dienste Bern (UPD) AG← PZM Psychiatriezentrum Münsingen AG
Bern's university psychiatric services absorbed the Münsingen psychiatric centre, CHF 111.5 million of assets in the 29 June filing, alongside a CHF 39.4 million recapitalisation of the merged entity. Public-sector healthcare is consolidating through the same register mechanics as private M&A. Most other large filings this week were intragroup absorptions, covered below.
CHF 111.5M (net assets)
Funding — Swiss rounds this week
Jul 2
CCRAFT SANE· Deep Tech
Neuchatel CSEM spin-out running the first independent pure-play foundry for thin-film lithium-niobate photonic chips for AI datacom and quantum. Led by Zurich's QBIT Capital, with Zuercher Kantonalbank, Apprecia Capital, Spacewalk and Blue Wonder Ventures; roughly CHF 3 to 3.5 million in public and cantonal support on top.
CHF 6.3M (USD 7.8M)
Venture round
Jun 30
infinity.swiss (NextBusiness AG)ZH· Fintech
Zurich AI accounting platform for Swiss SMEs, founded 2023, aiming at autonomous bookkeeping. Led by EquityPitcher Ventures, with Tenity, Backbone Ventures and angels Daniel Gutenberg and Lukas Speiser.
USD 3M
Seed
Court Watch — decisions ahead
Jul 4
Gamaya SAVD
extended
Jul 13
HUARUI Investments SAFR
extended
Jul 30
INSIDERCARS GmbHLU
extended
Jul 30
avobis GROUP AGZH
granted provisional · Kälin, Dr. Oliver
Aug 3
Lerch AG BauunternehmungZH
granted definitive
Aug 3
TES Transports SAVD
granted definitive · Zürcher Pierre-Yves
The Signals
Unlock the signals — free
Pre-deal signals scored before the press, federal procurement prints, the complete deal tape, the forward court calendar and buyable estates. Free, every Friday.
Free weekly newsletter. Unsubscribe anytime.
Based on 7,306 SOGC/SHAB publications processed this week. M&A data sourced from Swiss commercial registry filings (303 SOGC), press-reported transactions via web intelligence (7 EXA), and startup funding from Startupticker, Tech.eu, and company disclosures (2 rounds). Company distress scoring based on proprietary multi-signal model across 113,000 Swiss companies. Valuation benchmarks supplemented from Deloitte Swiss M&A reports and Dealsuite DACH data.
ValIndex scores every Swiss merger, capital move, board change and distress signal as it hits the register, links each to the company, its owners and its succession risk, and maps entire industries end to end. This edition's study, deals and signals are all live on the platform. Request access →